The Bulletin


.

Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry

  • Written by The Bulletin
  • Hubei Bafeng is one of the national pharmaceutical amino acid industrialization bases in China, with over 20 drug approval numbers;
  • After the acquisition is completed, Grand Pharma will become the pharmaceutical company with the most registration numbers of amino acid APIs in China;
  • Grand Pharma's amino acid industry has leading technological advantages, and its products are sold to more than 140 countries and regions around the world.

Read more: Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on...